Pharmaceutical

Nouscom extends Series C round to $82m for cancer vaccine trials

Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.

Mar 22, 2024 - 00:00
Nouscom extends Series C round to $82m for cancer vaccine trials
Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.
Read the original article

Tags:

Previous Article

Early AMR pipeline looks beyond traditional antibiotics

Next Article

Keytruda combination treatment for NSCLC falls short in Phase III

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AI database to bolster research for GLP1-RAs as precision medicines

AI database to bolster research for GLP1-RAs as precisi...

May 15, 2024

The science of viscous drug product filling: Pumps, pressure, and process optimization

The science of viscous drug product filling: Pumps, pre...

Oct 16, 2024

STAT+: White House drug shortage task force held rare in-person meeting with industry

STAT+: White House drug shortage task force held rare i...

Aug 3, 2023